Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,246 | 4,177 | 1,310 | 3,845 | N/A |
| Other current assets | 488 | 899 | 1,462 | 496 | 0 |
| TOTAL | $2,734 | $5,076 | $2,772 | $4,341 | $N/A |
| Non-Current Assets | |||||
| Intangibles | 0 | 0 | 0 | 14 | 0 |
| TOTAL | $N/A | $N/A | $N/A | $14 | $N/A |
| Total Assets | $2,734 | $5,076 | $2,772 | $4,355 | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,782 | 4,686 | 3,208 | 1,671 | 0 |
| Accrued Expenses | 2,605 | 1,685 | 1,530 | 1,566 | N/A |
| Other current liabilities | 1,041 | 1,408 | 1,587 | 1,347 | N/A |
| TOTAL | $9,428 | $8,779 | $6,325 | $4,584 | $N/A |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $9,428 | $8,779 | $6,325 | $4,584 | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 619 | 299 | 198 | N/A | N/A |
| Common Shares | 2,430 | 2,430 | 1,598 | 1,324 | N/A |
| Retained earnings | -243,480 | -240,585 | -233,027 | -227,461 | N/A |
| Other shareholders' equity | 51,268 | 51,445 | 51,433 | 51,154 | 0 |
| TOTAL | $-6,694 | $-3,703 | $-3,553 | $-229 | $N/A |
| Total Liabilities And Equity | $2,734 | $5,076 | $2,772 | $4,355 | $0 |